Stryker: The Policy Said One Thing, the Sales Records Another
The Stryker FCPA case produced a $13,283,523 settlement with the Securities and Exchange Commission in 2013 over alleged payments to government employees disguised as ordinary business expenses. A separate SEC resolution in 2018 addressed inflated hospital invoices, unauthorized distributors, and failures to check what intermediaries were doing. For someone inside the business, the revealing document could be a travel itinerary, a donation request, or the invoice a hospital wanted instead of the price it actually paid.
Stryker manufactures and distributes medical devices, including implants, surgical equipment, and neurotechnology products. The Michigan company’s Foreign Corrupt Practices Act settlements show how country subsidiaries and outside dealers can connect a global manufacturer to a hospital purchasing decision. Its subsidiaries’ financial results fed into the parent’s financial statements, so the local expense descriptions traveled back to the corporate books.
The 2013 SEC Order Followed Payments in Five Countries
The Securities and Exchange Commission’s October 24, 2013 order alleged approximately $2.2 million in unlawful payments to government employees in Mexico, Poland, Romania, Argentina, and Greece from approximately August 2003 through February 2008. The recipients included public health care professionals whose decisions could bring Stryker hospital business. The commission described consulting fees, travel expenses, donations, and commissions that concealed what those payments bought.
The order addressed both false books and records and failed internal accounting controls. The first concerned how Stryker described the payments, the second whether anyone checked the transactions behind them. Stryker had corporate anti-corruption policies, but the commission said they were inadequate and insufficiently implemented within its decentralized country operations.
The settlement required Stryker to surrender $7,502,635 in profits and pay a $3,500,000 civil penalty. The order also required $2,280,888 in prejudgment interest on those profits, completing the settlement total.
Mexico’s Legal Bill Kept a Hospital Contract
In Mexico, the commission alleged that a threatened loss of business became an invoice for legal services. Stryker Mexico had won a bid to supply knee and hip products to public hospitals. An employee of the government agency involved demanded a payment, threatening the contract if Stryker refused.
According to the order, Stryker Mexico directed an outside law firm to pay the official approximately $46,000. The firm then billed Stryker for legal services it had never provided, and Stryker recorded the payment as a legitimate legal expense. The company kept its winning bid and earned over $1.1 million in illicit profits on that contract, the commission alleged. In the commission’s account, the invoice named a service, while the payment protected a sale.
Poland’s Factory Visit Came With Aruba
The commission alleged that Stryker Poland paid for a public-hospital director and her husband to visit New York City and Aruba under the cover of a factory visit. The stated business purpose was a single-day tour of Stryker’s manufacturing and research facility in New Jersey. The company also paid for six nights in New York, two Broadway shows, and five days in Aruba, recording the spending as legitimate travel expenses.
The link to sales was in Stryker’s own paperwork. The tour form referred to a hospital tender already won and further purchases expected that year. For an insider familiar with customer travel and hospitality, the itinerary and the sales justification tell the story together: what the company called a visit, what it actually funded, and whose purchasing decision it wanted to influence.
Romania’s Sponsorship and Argentina’s Sales Commissions
In Romania, the commission alleged that conference and medical-event sponsorships concealed payments intended to win or retain public-hospital business. A salesperson’s request to fund an official’s lodging identified the expected return as a medical-device contract.
In Argentina, the commission alleged that Stryker routinely paid public-system physicians commissions of 20% to 25% of the related hospital sale, described as honoraria. In that account, a fee presented as professional compensation depended on the business the doctor brought in.
Greece’s Donation Had a Sales Target
The commission alleged that Stryker Greece’s $197,055 university donation funded a laboratory associated with a professor who also directed medical clinics at public hospitals. The business connection appeared in emails between country and regional management. A manager said the donation was necessary to secure future sales, and the regional manager asked what Stryker would receive for its sponsorship.
The answer, reproduced in the order, was explicit:
For the sponsorship we get the Spine business and a promise for more products in his Department. . .
Stryker country manager email quoted in the SEC’s October 24, 2013 order, paragraph 31
We see a sales bargain in that exchange. The commission alleged that Stryker recorded the installments as legitimate marketing expenses in its Donations and Grants account. The charitable payment went to a university, but the internal explanation connected it to the doctor’s influence over hospital business.
The 2018 SEC Order Reached India, China, and Kuwait
Stryker agreed to a $7,800,000 civil penalty in the Securities and Exchange Commission’s September 28, 2018 order, which addressed its operations in India, China, and Kuwait. The commission alleged internal accounting-control failures across those operations and a books-and-records violation involving India.
Stryker’s policies required documented transactions, approved and trained distributors, and access to their records. The commission’s account followed what happened when those requirements met actual sales.
India Had One Price for the Hospital and Another on the Invoice
According to the order, Stryker India generated approximately 85% of its revenue through third-party dealers. The commission alleged that certain private hospitals asked those dealers to inflate invoices for orthopedic products. Stryker India’s management had negotiated the hospital prices and approved the dealers’ margins. The hospitals paid those lower prices but passed the higher invoiced amounts to patients or their insurers. On the commission’s account, the extra money came from the people paying for care.
The order says Stryker received internal complaints and audited three dealers in 2012. Those audits exposed poor records and an instance of hospital-requested overbilling, but the corrective response stayed limited to the dealers audited. Audits in 2015 found that inflated invoicing had become more widespread.
The commission also described a records problem inside the subsidiary. A forensic review found no documentation for 144 out of 533 sampled transactions in Stryker India’s highest-risk and most compliance-sensitive accounts. Other payments had inadequate support, including consulting fees without an explanation of the services or hours billed. For a finance employee, the gap between a ledger entry and the work supposedly purchased was part of the case.
China’s Installation Records Hid Unapproved Sellers
The commission alleged that Stryker China’s Sonopet sales passed through at least 21 sub-distributors that had not been vetted, approved, or trained as company policy required. Stryker China sold the ultrasonic aspirator through a state-owned main distributor, followed by a network of other sellers. Some hospital sales involved several further levels of sub-distributors.
According to the order, Stryker China employees knew of and worked directly with certain unauthorized sellers. Installation records were sometimes falsified to conceal those sellers’ involvement. That makes an installation record more than a service document: it can show who actually participated in a sale when the approved distributor file tells a different story.
Kuwait’s Distributor Refused the Audit
The commission alleged that Stryker’s Kuwait distributor made at least $32,000 in improper daily-allowance payments to healthcare professionals attending Stryker events, even though Stryker had already paid their lodging, meals, and transportation. Most of that distributor’s Stryker sales went to Kuwait’s Ministry of Health for public hospitals.
The order says a former distributor employee had complained that the distributor paid bribes in connection with Stryker sales. Stryker had not previously tried to audit or otherwise review the distributor’s records despite that complaint. When Stryker did seek access, the distributor refused. We see the problem with treating an audit clause as a working control: the contract promised access, but the records stayed out of reach.
What Changed After the Earlier Settlement?
Stronger oversight appeared in both settlements. The 2013 order described expanded auditing and compliance staff. The 2018 order again described reforms, including centralized dealer documentation and more dealer audits. We see the gap between announcing a reform and making it work in a sales office.
The later order also required an independent consultant to evaluate controls over the intermediaries selling Stryker products. Its assignment included examining how policies were actually implemented and whether the compliance function had enough resources, authority, and independence. For an insider, that is the consequential comparison between the resolutions: what a company says its controls require and what its sales operation actually permits.
What the Medical-Device Business Makes Visible
Medical-device sales can separate the person approving a payment from the intermediary receiving it and the hospital official able to influence the purchase. Stryker’s cases put those roles inside country subsidiaries, dealerships, public hospitals, and the parent’s consolidated accounts. An employee who knows the customer, the negotiated price, or the purpose of a trip may explain something the expense category conceals.
The same need to look beyond the manufacturer’s ledger appears in Fresenius Medical Care. The 2022 Journal of Forensic and Investigative Accounting paper Fresenius Medical Care: A Case Study on the FCPA describes managers circumventing controls despite flagged transactions and written policies. The paper makes the response to warnings part of the story, alongside the original payment.
The commission’s separate Fresenius order alleged that shifting doctor payments to a supplier made expenses disappear from Fresenius’s own books:
With the costs shifted to West African Supplier, FMC books showed expenses were significantly lower, which enabled FMC executives to conceal the bribe payments to the hospital officials.
In the Matter of Fresenius Medical Care AG & Co. KGaA, SEC order, paragraph 22
That allegation shows why distributor records can matter as much as the manufacturer’s expense report. In Stryker’s later case, the commission traced inflated customer invoices, hidden sub-distributors, and refused access to dealer records. The commercial relationship determines where the explanation may sit.
The Records an Insider Can Explain
The useful whistleblower evidence in these cases connected a business decision to its payment and its description in the books. Stryker’s orders identify invoices, travel forms, donation emails, negotiated prices, installation records, internal complaints, and audit findings. Sales, finance, distributor, and compliance employees can see different parts of that connection in their ordinary work.
Eligible SEC whistleblower awards can pay 10% to 30% of the money collected in qualifying cases. Our whistleblower experts connect what you know about the sale to the payment and the records behind it, and bring in medical-device bribery whistleblower lawyers for your case.
You Know What the Invoice Leaves Out
If you know why a hospital wanted a different invoice, who approved the donation, or which distributor actually made the sale, speak with our whistleblower experts. We work beside you to build your strongest Foreign Corrupt Practices Act whistleblower case around those business facts and bring in whistleblower lawyers who understand medical-device sales.
